Recalls of generic Zantac believed to be contaminated by a carcinogen continue to flood in. Two other firms have declared recalls of ranitidine heartburn meds in 150 mg and 300 mg doses. The news arrived even as the degree of the drug returns increased with Mylan’s impromptu recall of three lots of nizatidine capsules last week because the API in them also held dangerous levels of NDMA.
Shortly after the Federal officials announced the voluntary recalls of some pharmacies over NDMA, a drug filled with a potential human carcinogen, many other pharmacies have recalled the common variety of heartburn drug Zantac, called ranitidine, from shelves.
Additional generic editions of Zantac are being taken down from pharmacy shelves after officials detected low levels of a possible carcinogens in the heartburn medication.
The Stryker Tritanium Acetabular Shell, which restores the human hip socket, is built from a titanium alloy covered with a unique kind of porous foam. The foam enables bone cells to bind with it and grow, thereby increasing joint stability. However, a 2018 report in the journal Arthroplasty Today by doctors at NYU Langone Orthopedic Hospitals described five hip implant failures related to Stryker’s Tritanium cups between 2011 and 2016.
After an initial golden age of promise, the medical implant industry has suffered a sharp backlash in recent years. Numerous implant systems and technologies have either failed to perform as promised or done more harm than good — some have even killed people. As recipients of these faulty devices have gone to the press or to court, the reputation of the medical implant industry has been dragged through the mud and then some.
According to the Chairman of Cardiovascular Medicine at the Cleveland Clinic, approximately 1 out of every 69 of his patients taking canagliflozin for five years will end up with a drug-related amputation. These amputation commonly involve the toe, foot, or part of the leg, and are reportedly twice as likely to occur in patients taking Invokana for several years as opposed to other diabetic drugs.
2332 South Broad Street
Philadelphia PA 19145
p: 215 462 3330 / f: 215-567-1941
